Navigation Links
Synthetic biology lab backed by £2 million award

Scientists at the University of Liverpool have been awarded 2M to build a state-of-the-art DNA synthesis facility, a capability offering much needed tools for genome engineering to the academic and private sectors.

This facility, named GeneMill will be part of the UK's focus on synthetic biology, identified by the Government as one of the 'Eight Great Technologies' in which Britain is, or can be, a world leader.

Synthetic biology involves the construction of artificial biological devices, pathways or networks or the re-engineering of existing natural ones. Key to this engineering process is the construction of parts or components, which are encoded in DNA. One of the biggest hurdles in synthetic biology is the creation and assembly of starting materials: modular bits of DNA that code for a particular function and are synthesised in the lab.

Creating such starting materials is time-consuming and expensive and a challenge that the Liverpool group of scientists will address through the GeneMill. Like traditional mills, scientists will take in raw materials and use them to create new products. In the GeneMill however, raw materials will be in the form of DNA blocks and, together with pre-existing blocks and DNA stretches from biological material, these will be woven into DNA constructs for re-engineering biology.

Through this approach the GeneMill will provide a rapid, cost-effective and accessible fabrication facility for DNA parts. By removing the complexity of manufacture for the user, GeneMill will allow researchers to focus on the design and testing of the re- engineered organisms which, amongst other areas, can be applied to produce novel chemicals, including new antibiotics and drugs and, at the large scale, feed stocks for the chemical industry.

Universities and Science Minister David Willetts said: "Synthetic biology is one of the eight great technologies of the future with the potential to underpin growth and create jobs in a low carbon economy. This investment in SynBio will hopefully stimulate even more interest and financial support and reinforce our efforts to develop a leading SynBio community in the UK."

The new laboratory will utilise expertise in the application of DNA and protein technologies and computational biology that already exist in the University's Centre for Genomic Research and in the Institute of Integrative Biology.

Plant biologist, Professor Anthony Hall, is the lead academic for the GeneMill project. He said: "This new lab will provide a resource for the whole of the North of England. It will add to a major concentration of technical expertise and facilities in synthetic and DNA technologies in Liverpool, which places the region at the forefront of research and development in this field."


Contact: Jamie Brown
University of Liverpool

Related biology news :

1. New synthetic biology technique boosts microbial production of diesel fuel
2. UC Santa Barbara researchers develop synthetic platelets
3. Synthetic diamond steps closer to next generation of high performance electrochemical applications
4. Synthetic Biology Scorecard finds federal agencies responding to bioethics report
5. Collagen-seeking synthetic protein could lead doctors to tumor locations
6. Synthetic biofilter wins through to the top Sweet 16 in Boston
7. Nottingham part of £20m investment for UK synthetic biology
8. Microchoreography: Researchers use synthetic molecule to guide cellular dance
9. Synthetic fuel could eliminate US need for crude oil
10. New report finds increase in media coverage of synthetic biology
11. Synthetic and biological nanoparticles combined to produce new metamaterials
Post Your Comments:
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig ... report titled, "DNA Synthesis and Biosecurity: Lessons Learned and ... Department of Health and Human Services guidance for synthetic ... 2010. --> --> ... also has the potential to pose unique biosecurity threats. ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... Md. , Nov. 30, 2015 ... development company committed to the fostering and monetization ... the current and prospective initiatives designed to create ... Chief Executive Officer of Spherix. "Based on published ... future licensees exceeds $50 billion and Spherix will ...
(Date:11/30/2015)... , Nov. 30, 2015  Champions Oncology, Inc. (CSBR), ... services to personalize the development and use of oncology ... Executive Officer, will be presenting at the LD MICRO ... Pacific Standard Time (PST).  The conference, held at the ... Angeles, CA , will feature 200 small/micro-cap companies ...
(Date:11/30/2015)... 30, 2015 TapImmune, Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for ... it will be presenting at the 8 th ... at 2.30 PM PT. Dr. John N. Bonfiglio ... be giving the presentation and will join TapImmune management ...
(Date:11/30/2015)... , Nov. 30, 2015  Aytu BioScience, Inc. (OTCQB: ... and related conditions, will present at two upcoming investor ... an interactive real-time virtual conference, to be held December ... Conference, to be held December 2 nd & ... and streamed live via webcast. ...
Breaking Biology Technology: